Functional researches showed that IGF2BP2 knockdown inhibited viability, proliferation, accelerates apoptosis of crizotinib-resistant A549 and H1299 cells, and inhibited crizotinib-resistant NSCLC tumor growth, indicating that IGF2BP2 knockdown alleviates crizotinib-resistant NSCLC progression. Here, IGF2BP2 is linked to non-small cell lung carcinoma.